Inari Medical Inc. (NARI) News
Filter NARI News Items
NARI News Results
|Loading, please wait...|
NARI News Highlights
- For NARI, its 30 day story count is now at 21.
- Over the past 16 days, the trend for NARI's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- The most mentioned tickers in articles about NARI are NOV, ALC and ALGN.
Latest NARI News From Around the Web
Below are the latest news stories about INARI MEDICAL INC that investors may wish to consider to help them evaluate NARI as an investment opportunity.
In the realm of stock market movements, insider trading activity is often a significant indicator that investors keep a close eye on.
IRVINE, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the close of its acquisition of LimFlow S.A., a privately-held pioneer in limb salvage for patients with chronic limb-threatening ischemia (CLTI). “The close of the LimFlow acquisition allows us to begin to integrate this exciting technology that is offering ne
Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on the adoption of products is a concern.
Investors are optimistic about Boston Scientific (BSX), led by growing demand for WATCHMAN FLX devices and upbeat guidance.
Alcon's (ALC) Clareon Vivity IOL highlights proven results and high levels of patient satisfaction. It will offer a similar halo profile compared with a monofocal IOL.
Charles River's (CRL) RMS organic revenue growth is primarily driven by research model services, particularly the Insourcing Solutions business.
Globus Medical's (GMED) legacy business continues to drive share growth across its U.S. spine and trauma portfolios in the third quarter.
Investors are optimistic about Align Technology (ALGN), led by its strong global presence.
Zimmer Biomet (ZBH) gains from solid strategic execution and increasing traction in innovations in the third quarter.
Myriad Genetics' (MYGN) third-quarter 2023 revenues increase year over year, driven by strong testing volume improvement across all its businesses.